John P. Parisot - Concepedia

Concepedia

Author

John P. Parisot

The University of Melbourne

Also Known As

J P Parisot, J Parisot, J. P. Parisot, J.P. Parisot, John P Parisot, John P. Parisot, John Parisot, Parisot, John P.

24

Publications

1.4K

Citations

15

H-Index

34

Concepts

All Affiliations

The University of Melbourne Walter and Eliza Hall Institute of Medical Research Peter MacCallum Cancer Centre Monash University University of Dundee

JP

About

John P. Parisot is an author at The University of Melbourne specializing in medicine, drug discovery, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	863
2	Cell Biology	6	6	437
3	Natural Sciences	4	4	314
4	Biochemistry	2	2	117
5	Biology	1	1	12

John P. Parisot

×

17

Publications

1.4K

Citations

15

H-Index

	Year	Citations
Structure-guided design of a selective BCL-XL inhibitor Guillaume Lessène, Peter E. Czabotar, Brad E. Sleebs, Nature Chemical Biology Drug TargetMedicineRational Drug DesignPharmacotherapySelective Bcl-xl Inhibitor	2013	370
Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing Stephen Q. Wong, Jason Li, Angela Tan, BMC Medical Genomics	2014	248
An <i>in vivo</i> large-scale chemical screening platform using <i>Drosophila</i> for anti-cancer drug discovery Lee Willoughby, Tanja Schlosser, Samuel A. Manning, Disease Models & Mechanisms Drug TargetHit IdentificationPyrimidine BiosynthesisMolecular BiologyAnti-cancer Drug Discovery	2012	133
Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line John P. Parisot, Xiangdong Hu, Mario DeLuise, British Journal of Cancer Breast OncologyAltered ExpressionMedicineCancer GrowthBreast Cancer	1999	87
MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines John Zalcberg, Hu Xf, A Slater, Prostate Cancer and Prostatic Diseases Multidrug ResistanceTumor SuppressorProstatic DiseaseMdr1 Gene ExpressionRadiation Oncology	2000	73
Quinazoline Sulfonamides as Dual Binders of the Proteins B-Cell Lymphoma 2 and B-Cell Lymphoma Extra Long with Potent Proapoptotic Cell-Based Activity Brad E. Sleebs, Peter E. Czabotar, Wayne J. Fairbrother, Journal of Medicinal Chemistry	2011	69
Trypanothione Reductase High-Throughput Screening Campaign Identifies Novel Classes of Inhibitors with Antiparasitic Activity Georgina A. Holloway, William N. Charman, Alan H. Fairlamb, Antimicrobial Agents and Chemotherapy Bioorganic ChemistryHit IdentificationAntiparasitic AgentLead IdentificationPharmacotherapy	2009	65
Discovery of Potent and Selective Benzothiazole Hydrazone Inhibitors of Bcl-X<sub>L</sub> Brad E. Sleebs, W. Kersten, Sanji Kulasegaram, Journal of Medicinal Chemistry PharmacotherapyChemistryCancer BiologyPharmaceutical ChemistryTumor Biology	2013	64
An Efficient High-Throughput Screening Method for MYST Family Acetyltransferases, a New Class of Epigenetic Drug Targets Hendrik Falk, Theresa Connor, Hong Yang, SLAS DISCOVERY Mixed-phenotype Acute LeukemiaGeneticsEpigenetic ChangeMolecular BiologyGene Characterization	2011	56
Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening Georgina A. Holloway, Jonathan B. Baell, Alan H. Fairlamb, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryAfrican TrypanosomiasisTrypanothione Reductase InhibitorMedicine	2006	52

Page 1